Ensemble Therapeutics announced the initiation of a two-part Collaborative R&D agreement with big pharma partners Novartis.
The pharma partners have entered into a strategic development agreement for Ensemble’s most advanced proprietary program that targets the inflammatory cytokine IL-17, and for a new program to discover novel small molecule treatments against undisclosed drug targets specified by Novartis using Ensemble’s proprietary drug discovery platforms.
Under the terms of the pharma partners agreement, Ensemble will receive an undisclosed upfront payment from Novartis and is also eligible to receive potential success-based development and sales milestone payments.
In addition, Ensemble, one of the pharma partner, will receive tiered royalties on potential future sales of products that may arise from the collaboration.
Novartis, the other of the pharma partners, will also provide research funding to Ensemble during the term of the collaboration.
Ensemble’s class of IL-17 antagonists licensed by Novartis represent the potential for first-in-class, orally active, small molecule inhibitors of this important, clinically-validated target.
Report: Inflammatory Partnering 2007-2013
Report: Partnering Deals and Alliances with Novartis
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity